Table 1 Clinical studies reporting effects of dopamine on splanchnic haemodynamics
Reference | n | Drug (μg/kg per min) | Splanchnic blood flow | pHi or PCO2 gap | Comments |
|---|---|---|---|---|---|
[27] | 10 | Dopamine 5 | LD ↓ | PCO2 gap = | Laser Doppler study; cross-over trial |
|  |  | Dobutamine 5 | LD ↑ | PCO2 gap ↓ |  |
[29] | 16 | Dopamine 3 | NA | pHi = | Â |
[28] | 11 | Dopamine 3 + norepinephrine | HSBF ↑ | pHi = | Increase in fractional splanchnic flow when low before dopamine |
[30] | 10 | Dopamine 2.5 | = | pHi = | Splanchnic blood flow was measured by ICG clearance |
|  | 10 | versus dopexamine 1 | ↑ | pHi ↑ |  |
[31] | 9 | Dopamine 4 (2.1–9) | HSBF ↑ | NA | Decrease in splanchnic VO2; dopamine infused to achieve increase of 25% in cardiac index |
[32] | 5 | Dopamine 16 | HSBF ↑ |  |  |
|  | 5 | versus norepinephrine 0.13 | ≈ |  |  |
[34] | 10 | Dopamine 26 | NA | pHi ↓ | Dopamine and norepinephrine titrated to achieve MAP ≥ 75 mmHg |
|  | 10 | versus norepinephrine 0.18 |  | pHi ↑ |  |
[35] | 10 | Dopamine 26 | Â | Â | Switch from dopamine to norepinephrine or epinephrine in moderate septic shock |
| Â | Â | versus norepinephrine 0.18 | HSBF = | PCO2 gap = | Â |
| Â | Â | versus epinephrine 0.12 | HSBF = | PCO2 gap = | Â |